{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:32:02Z","timestamp":1791379922147,"version":"4.3.3"},"reference-count":48,"publisher":"MedWorks Media","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Objective\nTo evaluate the efficacy and tolerability of adjunct extended release quetiapine fumarate (quetiapine XR) in patients with generalized anxiety disorder (GAD) and inadequate response to selective serotonin reuptake inhibitors\/ serotonin norepinephrine reuptake inhibitors (SSRI\/SNRIs).\nMethods\n11-week (1-week single-blind placebo run-in; 8-week randomized treatment; 2-week post-treatment period), double-blind, placebo-controlled study. Patients were randomized to quetiapine XR or placebo adjunct to SSRI\/SNRI. 50 mg initial dose; 150 mg\/day, Day 3; 300 mg\/day, Weeks \u00d7 and 4 if indicated (Clinical Global Impressions-Severity of Illness [CGI-S] \u2265 4; 150 mg\/day tolerated). Primary endpoint: change from randomization to Week 8 in HAM-A total score. Secondary variables: Hamilton Rating Scale for Anxiety (HAM-A) psychic\/somatic clusters, response and remission; and CGI-S.\nResults\n409 patients were randomized to quetiapine XR (n = 209) or placebo (n = 200); 41% and 55% of patients, respectively, had dose increases (300 mg\/day). Week 8 mean change in HAM-A total score was not statistically significant for quetiapine XR (\u201310.74; p = 0.079) versus placebo (\u20139.61). Secondary variables were generally consistent with the primary analysis, except a significant reduction in HAM-A total score at Week 1 (\u20136.45, quetiapine XR versus \u20134.47, placebo; p &lt; 0.001); significant improvements in HAM-A psychic cluster (p &lt; 0.05) and CGI-S total (p &lt; 0.05) scores at Week 8. Adverse events (.10% either group) were dry mouth, somnolence, sedation, headache, and dizziness.\nConclusions\nIn patients with GAD and inadequate response to SSRI\/SNRI, adjunct quetiapine XR did not show a statistically significant effect for the primary endpoint at Week 8, although some secondary endpoints were statistically significant versus placebo. Quetiapine XR was generally well tolerated.<\/jats:p>","DOI":"10.64719\/pb.4062","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"5-31","source":"Crossref","is-referenced-by-count":0,"title":["Extended Release Quetiapine Fumarate (Quetiapine XR) as Adjunct Therapy in Patients with Generalized Anxiety Disorder and a History of Inadequate Treatment Response: A Randomized, Double-Blind Study"],"prefix":"10.64719","volume":"44","author":[{"given":"Arifulla","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Mezhebovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahua","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Leathers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Bruce SE, Yonkers KA, Otto MW et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. 2005;162:1179\u20131187.","DOI":"10.1176\/appi.ajp.162.6.1179"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Pollack MH. Refractory generalized anxiety disorder. J Clin Psychiatry. 2009;70(Suppl 2):32\u201338.","DOI":"10.4088\/JCP.s.7002.06"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16:162\u2013171.","DOI":"10.1002\/da.10065"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Baldwin DS, Anderson IM, Nutt DJ et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005;19:567\u2013596.","DOI":"10.1177\/0269881105059253"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders\u2014First Revision. World J Biol Psychiatry. 2008;9:248\u2013312.","DOI":"10.1080\/15622970802465807"},{"key":"ref6","unstructured":"Canadian Psychiatric Association. Management of Anxiety Disorders. Can J Psychiatry. 2006;51(Suppl 2):1S\u201393S."},{"key":"ref7","unstructured":"NICE guidelines. Anxiety: Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Available at: www.nice.org.uk\/CG022NICEguidelines Accessed: 4\/1\/2010."},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Rickels K, Rynn M, Iyengar M et al. Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database. J Clin Psychiatry. 2006;67:41\u201347.","DOI":"10.4088\/JCP.v67n0107"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Montgomery SA, Sheehan DV, Meoni P et al. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res. 2002;36:209\u2013217.","DOI":"10.1016\/S0022-3956(02)00005-5"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Katzman MA, Vermani M, Jacobs L et al. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. J Anxiety Disord. 2008;22:1480\u20131486.","DOI":"10.1016\/j.janxdis.2008.03.002"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Lohoff FW, Etemad B, Mandos LA et al. Ziprasidone treatment of refractory generalized anxiety disorder: a placebo-controlled, double-blind study. J Clin Psychopharmacol. 2010;30:185\u2013189.","DOI":"10.1097\/JCP.0b013e3181d21951"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Khan A, Joyce M, Atkinson S et al. A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2011;31:418\u2013428.","DOI":"10.1097\/JCP.0b013e318224864d"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Bandelow B, Chouinard G, Bobes J et al. Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol. 2010;13:305\u2013320.","DOI":"10.1017\/S1461145709990423"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Merideth C, Cutler AJ, She F et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in the acute treatment of generalized anxiety disorder (GAD): a randomized, placebo- and active-controlled study. Int Clin Psychopharmacol. 2011 In press.","DOI":"10.1097\/YIC.0b013e32834d9f49"},{"key":"ref15","unstructured":"Magi K, Mezhebovsky I, She F et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with generalised anxiety disorder (GAD) World J Biol Psychiatry. 2009;10:239."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Katzman MA, Brawman-Mintzer O, Reyes EB et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol. 2011;26:11\u201324.","DOI":"10.1097\/YIC.0b013e32833e34d9"},{"key":"ref17","unstructured":"AstraZeneca. Seroquel XR\u2014Summary of Product Characteristics for Ireland. Available at: http:\/\/www.medicines.ie\/medicine\/13032\/SPC\/Seroquel1XR150mg%2c1150mg%2c1200mg%2c1300mg%2c1400mg1prolonged-release1tablets\/ Accessed: 5\/5\/2011."},{"key":"ref18","unstructured":"AstraZeneca. Seroquel XR US Prescribing information. Available at: http:\/\/www1.astrazeneca-us.com\/pi\/seroquelxr.pdf Accessed: 5\/5\/2011."},{"key":"ref19","unstructured":"American Psychiatric Association, eds. Diagnostic and Statistical Manual of Mental Disorders. 4th. Washington, DC: American Psychiatric Association; 1994."},{"key":"ref20","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22\u201333."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50\u201355.","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology publication. Washington, DC: US Department of Health, Education and Welfare; 1976. Clinical Global Impressions; pp. 218\u2013222.","DOI":"10.1037\/e591322011-001"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Endicott J, Nee J, Harrison W et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321\u2013326.","DOI":"10.1037\/t49981-000"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Posner K, Oquendo MA, Gould M et al. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA\u2019s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164:1035\u20131043.","DOI":"10.1176\/ajp.2007.164.7.1035"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11\u201319.","DOI":"10.1111\/j.1600-0447.1970.tb02066.x"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672\u2013676.","DOI":"10.1192\/bjp.154.5.672"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Rosenbaum JF, Fava M, Hoog SL et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77\u201387.","DOI":"10.1016\/S0006-3223(98)00126-7"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Michelson D, Fava M, Amsterdam J et al. Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry. 2000;176:363\u2013368.","DOI":"10.1192\/bjp.176.4.363"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika. 1988;75:383\u2013386.","DOI":"10.1093\/biomet\/75.2.383"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Pinson L, Gray GE. Psychopharmacology: number needed to treat: an underused measure of treatment effect. Psychiatr Serv. 2003;54:145\u2013146. 154.","DOI":"10.1176\/appi.ps.54.2.145"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Khan A, Khan S, Brown WA. Are placebo controls necessary to test new antidepressants and anxiolytics? Int J. Neuropsychopharmacol. 2002;5:193\u2013197.","DOI":"10.1017\/S1461145702002912"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Fava M, Evins AE, Dorer DJ et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72:115\u2013127.","DOI":"10.1159\/000069738"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Katz MM, Halbreich UM, Bowden CL et al. Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants. Neuropsychopharmacology. 2002;27:319\u2013328.","DOI":"10.1016\/S0893-133X(02)00329-9"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66:1321\u20131325.","DOI":"10.4088\/JCP.v66n1016"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Lydiard RB, Rickels K, Herman B et al. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol. 2009:1\u201313.","DOI":"10.1017\/S1461145709990460"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Bauer M, Pretorius HW, Constant EL et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70:540\u2013549.","DOI":"10.4088\/JCP.08m04629"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Bortnick B, El-Khalili N, Banov M et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: A placebo-controlled, randomized study. J Affect Disord. 2011;128:83\u201394.","DOI":"10.1016\/j.jad.2010.06.031"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Cutler AJ, Montgomery SA, Feifel D et al. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 2009;70:526\u2013539.","DOI":"10.4088\/JCP.08m04592"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"El-Khalili N, Joyce M, Atkinson S et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13:917\u2013932.","DOI":"10.1017\/S1461145710000015"},{"key":"ref40","unstructured":"Purdon SE, Malla A, Labelle A et al. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci. 2001;26:137\u2013149."},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Liebowitz M, Lam RW, Lepola U et al. Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 2010;27:964\u2013976.","DOI":"10.1002\/da.20740"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Weisler R, Joyce M, McGill L et al. Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr. 2009;14:299\u2013313.","DOI":"10.1017\/S1092852900020307"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Nyberg S, Widzowski D. Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties. Eur Psychiatry. 2010;25:1446.","DOI":"10.1016\/S0924-9338(10)71429-2"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Jensen NH, Rodriguiz RM, Caron MG et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine\u2019s antidepressant activity. Neuropsychopharmacology. 2008;33:2303\u20132312.","DOI":"10.1038\/sj.npp.1301646"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Owens MJ, Krulewicz S, Simon JS et al. Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. Neuropsychopharmacology. 2008;33:3201\u20133212.","DOI":"10.1038\/npp.2008.47"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Arvanitis LA, Miller BG. the Seroquel Trial 13 study group. Multiple fixed doses of \u201cSeroquel\u201d (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997;42:233\u2013246.","DOI":"10.1016\/S0006-3223(97)00190-X"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Kahn RS, Schulz SC, Palazov VD et al. Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68:832\u2013842.","DOI":"10.4088\/JCP.v68n0603"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Timdahl K, Carlsson A, Stening G. An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Hum Psychopharmacol. 2007;22:315\u2013325.","DOI":"10.1002\/hup.853"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:24:24Z","timestamp":1791314664000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/extended-release-quetiapine-fumarate-quetiapine-xr-as-adjunct-therapy-in-patients-with-generalized-anxiety-disorder-and-a-history-of-inadequate-treatment-response-a-randomized-double-blind-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4062","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}